Connection between cell phone use, p53 gene expression in different zones of glioblastoma multiforme and survival prognoses

Rare Tumors

Volumn 6, Issue 3, 2014, Pages 116-120

  Akhavan Sigari, Reza ^a   Baf, Morteza Mazloum Farsi ^b   Ariabod, Vahid ^b   Rohde, Veit ^a   Rahighi, Saeed ^b  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

Author keywords

Glioblastoma multiforme; P53 gene expression; Reverse transcriptase polymerase chain reaction

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE MUTATION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MOBILE PHONE; OVERALL SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME; TUMOR SUPPRESSOR GENE;

EID: 84905752946     PISSN: 20363605     EISSN: 20363613     Source Type: Journal    
DOI: 10.4081/rt.2014.5350     Document Type: Article

References (32)

1. McLendon RE, Rich JN. Glioblastoma Stem cells: a neuropathologist's view. J Oncol 2011;2011:397195.
2. Utsuki S, Oka H, Suzuki S, et al. Pathological and clinical features of cystic and noncystic glioblastomas. Brain Tumor Pathol 2006;23:29-34.
3. Brat DJ, Prayson RA, Ryken TC, Olson JJ. Diagnosis of malignant glioma: role of neuropathology. J Neurooncol 2008;89: 287-311.
4. Demuth T, Berens ME. Molecular mechanisms of glioma cell migration and invasion. J Neurooncol 2004;70:217-28.
5. Groszer M, Erickson R, Scripture-Adams DD, et al. PTEN negatively regulates neural stem cell self-renewal by modulating G0-G1 cell cycle entry. Proc Natl Acad Sci USA 2006;103:111-6.
6. Maher EA, Furnari FB, Bachoo RM, et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev 2001;15:1311-33.
7. Ohgaki H. Genetic pathways to glioblastomas. Neuropathol Off J Jpn Soc Neuropathol 2005;25:1-7.
8. Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004;64: 6892-9.
9. Shiraishi S, Tada K, Nakamura H, et al. Influence of p53 mutations on prognosis of patients with glioblastoma. Cancer 2002;95:249-57.
10. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10.
11. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31.
12. Newcomb EW, Cohen H, Lee SR, et al. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes. Brain Pathol Zurich Switz 1998;8:655-67.
13. Watanabe K, Sato K, Biernat W, et al. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res Off J Am Assoc Cancer Res 1997;3:523-30.
14. Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2010;2:a001008.
15. Mukundan S, Holder C, Olson JJ. Neuroradiological assessment of newly diagnosed glioblastoma. J Neurooncol 2008;89:259-69.
16. Neubauer A, Neubauer B, He M, et al. Analysis of gene amplification in archival tissue by differential polymerase chain reaction. Oncogene 1992;7:1019-25.
17. Ishioka C, Frebourg T, Yan YX, et al. Screening patients for heterozygous p53 mutations using a functional assay in yeast. Nat Genet 1993;5:124-9.
18. Prives C, Manfredi JJ. The continuing saga of p53-more sleepless nights ahead. Mol Cell 2005;19:719-21.
19. Akyüz N, Boehden GS, Süsse S, et al. DNA substrate dependence of p53-mediated regulation of double-strand break repair. Mol Cell Biol 2002;22:6306-17.
20. Sarkar C, Sinha S, Sharma MC, et al. Supratentorial glioblastoma in adults: identification of subsets and their clinical correlation. Brain Tumor Pathol 2004;21:7-12.
21. Burton EC, Lamborn KR, Forsyth P, et al. Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors. Clin Cancer Res Off J Am Assoc Cancer Res 2002;8:180-7.
22. Cheng Y, Ng HK, Ding M, et al. Molecular analysis of microdissected de novo glioblastomas and paired astrocytic tumors. J Neuropathol Exp Neurol 1999;58: 120-8.
23. Sarkar C, Ralte AM, Sharma MC, Mehta VS. Recurrent astrocytic tumours - a study of p53 immunoreactivity and malignant progression. Br J Neurosurg 2002;16: 335-42.
24. Chozick BS, Pezzullo JC, Epstein MH, Finch PW. Prognostic implications of p53 overexpression in supratentorial astrocytic tumors. Neurosurgery 1994;35:831-8.
25. Sidransky D, Mikkelsen T, Schwechheimer K, et al. Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 1992;355:846-7.
26. Kikuchi T, Rempel SA, Rutz HP, et al. Turcot's syndrome of glioma and polyposis occurs in the absence of germ line mutations of exons 5 to 9 of the p53 gene. Cancer Res 1993;53:957-61.
27. Broaddus WC, Liu Y, Steele LL, et al. Enhanced radiosensitivity of malignant glioma cells after adenoviral p53 transduction. J Neurosurg 1999;91:997-1004.
28. Kraus JA, Glesmann N, Beck M, et al Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in longterm survivors of glioblastoma multiforme. J Neurooncol 2000;48:89-94.
29. Newcomb EW, Cohen H, Lee SR, et al. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes. Brain Pathol Zurich Switz 1998;8:655-67.
30. Baxendine-Jones J, Campbell I, Ellison D. p53 status has no prognostic significance in glioblastomas treated with radiotherapy. Clin Neuropathol 1997;16:332-6.
31. Schiebe M, Ohneseit P, Hoffmann W, et al. Analysis of mdm2 and p53 gene alterations in glioblastomas and its correlation with clinical factors. J Neuroonco 2000;49:197-203.
32. Tada M, Matsumoto R, Iggo RD, et al. Selective sensitivity to radiation of cerebral glioblastomas harboring p53 mutations. Cancer Res 1998;58:1793-7.